← Back to Search

Iron Chelator

Deferiprone Therapy for Heart Attack (MIRON-DFP Trial)

Phase 1 & 2
Recruiting
Led By Keyur P Vora, MD FACC
Research Sponsored by Rohan Dharmakumar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Index Anterior wall STEMI, based on American Heart Association guidelines diagnostic criteria: Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain, arm pain, diaphoresis, or any anginal equivalent) and ECG: New or presumed new ST-segment elevation at the J point in two or more contiguous leads with the cut-off points ≥0.2 mV in leads V1, V2, V3, or V4 and ≥ 0.1 mV in other leads, Elevated biomarkers (Troponin), Coronary angiogram with primary PCI to occur irrespective of the duration of the symptoms.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

MIRON-DFP Trial Summary

This trial tests if a drug can reduce iron in the heart of people who had a heart attack, to help them recover.

Who is the study for?
This trial is for adults who've recently had a specific type of heart attack (anterior wall STEMI) and are about to have a procedure to open their blocked arteries. They must not have had previous heart attacks or procedures, severe kidney issues, known allergies to MRI contrast agents, or be pregnant. Their body weight should be under 309 lbs., and they can't have certain blood disorders or liver problems.Check my eligibility
What is being tested?
The study tests if Deferiprone tablets can reduce iron in the damaged area of the heart after a hemorrhagic myocardial infarction. Patients will either receive Deferiprone or a placebo randomly, alongside standard care including an MRI scan to guide treatment.See study design
What are the potential side effects?
Deferiprone may cause side effects like nausea, vomiting, joint pain, and changes in liver function tests. It might also lead to neutropenia (a drop in white blood cells), which increases infection risk.

MIRON-DFP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had a specific type of heart attack affecting the front wall of my heart, confirmed by symptoms, ECG changes, and high heart markers.

MIRON-DFP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Therapeutic procedure
Secondary outcome measures
Safety and Tolerability - Rate of Discontinuation
Safety and Tolerability - Reversibility of Side Effects without Treatment
Safety and Tolerability - Severe Side Effects
+2 more
Other outcome measures
Treatment Effect: Fat Infiltration

MIRON-DFP Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Hemorrhagic Myocardial Infarction - DeferiproneActive Control1 Intervention
Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
Group II: Non-hemorrhagic Myocardial Infarction - DeferiproneActive Control1 Intervention
Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage
Group III: Hemorrhagic Myocardial Infarction - PlaceboPlacebo Group1 Intervention
Enrolled patients with CMR confirmed presence of intramyocardial hemorrhage
Group IV: Non-hemorrhagic Myocardial Infarction - PlaceboPlacebo Group1 Intervention
Enrolled patients with CMR confirmed absence of intramyocardial hemorrhage

Find a Location

Who is running the clinical trial?

Rohan DharmakumarLead Sponsor
5 Previous Clinical Trials
200,620 Total Patients Enrolled
Cardio-theranostics LLCUNKNOWN
Lipomed AGUNKNOWN

Media Library

Deferiprone (Iron Chelator) Clinical Trial Eligibility Overview. Trial Name: NCT05604131 — Phase 1 & 2
Heart Attack Research Study Groups: Hemorrhagic Myocardial Infarction - Deferiprone, Non-hemorrhagic Myocardial Infarction - Deferiprone, Hemorrhagic Myocardial Infarction - Placebo, Non-hemorrhagic Myocardial Infarction - Placebo
Heart Attack Clinical Trial 2023: Deferiprone Highlights & Side Effects. Trial Name: NCT05604131 — Phase 1 & 2
Deferiprone (Iron Chelator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05604131 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to participate in this scientific experimentation?

"This clinical trial is seeking sixty participants aged 18 to 75 who have experienced myocardial infarction. Criteria for inclusion are manifesting symptoms of myocardial ischemia, including chest pain and shortness of breath; elevated biomarkers (Troponin); coronary angiogram with primary PCI regardless of the length of time since onset; and new or presumed new ST-segment elevation on ECG at 0.2 mV in leads V1, V2, V3 or V4, and 0.1 mV in other leads."

Answered by AI

How many individuals are actively enrolled in this clinical investigation?

"Affirmative. According to the findings on clinicaltrials.gov, this medical experiment is currently recruiting participants, which commenced posting on November 1st 2022 and was recently updated on November 2nd 2022. The team needs 60 patients from a single site."

Answered by AI

Are participants still eligible to join this experiment?

"According to the information accessible on clinicaltrials.gov, this medical experiment is actively searching for participants, with initial posting of November 1st 2022 and most recent update being made on November 2nd 2022."

Answered by AI

Could you provide an assessment of the risks of Non-hemorrhagic Myocardial Infarction - Deferiprone for patients?

"Due to the limited data on safety and efficacy, Non-hemorrhagic Myocardial Infarction - Deferiprone received a score of 1."

Answered by AI

Does this medical trial accept individuals who are of legal age?

"Per the eligibility criteria, individuals aged 18 to 75 are suitable for this trial. Additionally, there are 11 trials designed specifically for minors and 357 clinical studies dedicated to seniors."

Answered by AI
~35 spots leftby Jul 2025